Tango Therapeutics, Inc. (TNGX) Stock Price & Analysis

Tango Therapeutics, Inc. (TNGX) closed at USD 22.23 on Wednesday, October 28, 2026, down 2.88% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 22.89; the Oct 28, 2026 session ranged USD 22.14–23.71 on volume of 3,309,657 shares. Market capitalization is $3.75B, with a 52-week range of USD 7.37–34.39 (NGM). Source: Nexqual, retrieved October 29, 2026 at 08:45 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TNGX.md

Key facts (TNGX)

• Last four reported quarters (through Jun 30, 2026): revenue $53.8M, net income -$124M (-229.9% margin), free cash flow -$144M (SEC filings).
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $5.1M; 0 not under a Rule 10b5-1 plan ($0K); 7 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (13 analysts), mean target USD 47.09 (range 24–69).
• Next earnings: 2026-11-04, EPS estimate USD -0.35, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TNGX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TNGX)

P/S 69.7x · P/B 3.7x · FCF yield -3.85% · Earnings yield -3.30%

Insider sales (SEC Form 4, open-market, last ~7 months) (TNGX)

8 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (TNGX)

Consensus Buy (mean 2.00 on a 1–5 scale), 13 analysts; mean target USD 47.09 (low 24, high 69).

Rating changes, last 120 days:

TNGX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

TNGX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

TNGX analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 08:45 UTC)

Technical Analysis (TNGX)

Nexqual's technical model rates TNGX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 08:45 UTC.

Analyst Ratings (TNGX)

Wall Street analysts rate TNGX "Buy" based on 13 analysts, with a mean price target of USD 47.09 (range USD 24–69), per Nexqual as of October 29, 2026 at 08:45 UTC.

Earnings (TNGX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 08:45 UTC.

Financials & Fundamentals (TNGX)

Source: Nexqual, October 29, 2026 at 08:45 UTC.

Financial Health Score (TNGX)

Nexqual rates Tango Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 08:45 UTC.

Ownership (TNGX)

Source: Nexqual, October 29, 2026 at 08:45 UTC.

Leadership (TNGX)

Tango Therapeutics, Inc. is led by Malte Peters, President, CEO & Director, per Nexqual as of October 29, 2026 at 08:45 UTC.

Major Backers & Investors (TNGX)

Notable institutional backers of Tango Therapeutics, Inc. include RTW Investments LP, FMR, LLC, Farallon Capital Management LLC, according to Nexqual as of October 29, 2026 at 08:45 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 08:45 UTC.

From Tango Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• We also rely on trade secrets relating to our proprietary target discovery technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of precision oncology that may be important for the development of our business and product candidates.
• We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit.

Partnerships

• We have a clinical collaboration agreement with Eli Lilly and Company, or Lilly, that will supply Verzenio® (abemaciclib), a CDK4/6 inhibitor, for use in combination with TNG456 in our ongoing Phase 1/2 clinical trial focused on MTAP-deleted GBM.
• We have an ongoing clinical collaboration with Revolution Medicines, Inc., or RevMed, and are currently combining vopimetostat with daraxonrasib, a RAS(ON) multi-selective inhibitor, and separately with zoldonrasib, a RAS(ON) G12D-selective inhibitor, in MTAP-deleted, RAS-mutant pancreatic and lung cancer in a Phase 1/2 clinical trial.

Legal & Regulatory Risks (Item 1A, quoted)

• We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.
• We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
• We may seek a breakthrough therapy designation for some of our product candidates.
• We may seek accelerated approval of our current or future product candidates using the FDA's accelerated approval pathway. Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 08:45 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt